Bio Relief: US FDA Rules On Biosimilars Naming
The suspense is over: the US Food and Drug Administration (FDA) has made their decision.
News and Views in Healthcare: This Weekend's Top 3 Reads
What's on our radar in the healthcare world.
US FDA Accepts Mylan Biologics License Application (BLA)
Decision slated for early September.
Should Biosimilars Be Interchangeable with Biologics?
Interchangeability is the real question.
News and Views in Healthcare: Today's Top 3 Reads
Today's top healthcare news with a focus on the biosimilars industry.
Biotech Movers and Shakers: Eye on Oncobiologics
We'll feature the latest biotechnolology "movers and shakers"--and how they are impacting the biosimilars industry.
What President Trump Means for Big Pharma
Patients may save money on prescriptions---and cut down pharma's profits.
Medicare Reimbursing for Inflectra, Pfizer's Infliximab Biosimilar
The New Wrinkle in the US Biosimilars Approval Process
GPhA takes issue with FDA timeline.
US Biosimilar Reimbursement: Medicare and Medicaid
Mylan and Momenta Pharma Combine Biosimilar Forces
Mylan and Momenta Pharmaceuticals to develop, manufacture, and commercialize six of Momenta’s current biosimilar candidates.
FDA Finalizes Biosimilar Guidance
Was waiting the worst part?
Biosimilar Shows Promise Treating Chemotherapy-Induced Anemia in Elderly Patients
Developments in Biosimilars for Rheumatic Diseases
Biologic Agents Continue to Outpace Overall Pharma Spending Growth
How Do US Payers View Biosimilars From a Cost Perspective?
US payers do not expect the biosimilars market to be like the generics market.
What Were the Top Five Legal Issues in Biosimilars in 2016?
Branded Trastuzumab HERITAGE Study Published in JAMA
The BPCIA Patent Dance – What Biosimilar Companies Need To Know
Live webcast on what biosimilar companies need to know.
Mundipharma Establishes Disti License from Celltrion
BioCND to Develop Lucentis Biosimilar
What Are the Eight Barriers to Biosimilar Development?
Quality, safety, and knowledge are critical.
Six Months Makes a Difference: Physicians' Attitudes About Biosimilars
A notably larger percentage of US physicians say they intend to prescribe biosimilars in the coming three years.
Top 5 Biosimilar Facts for Pharmacists
What do pharmacists need to know?
Looking to 2017: Market Access for Biosimilars
Convincing data to support the safety and effectiveness is key.
Biosimilars in Development for Chinese Market Via Sanofi Partnership
Celltrion's Biosimilar Granted Marketing Approval Recommendation
A biosimilar to Roche’s Rituxan, Truxima (rituximab) is indicated for blood cancer.
CRISPR Biotechs Create IP Pact: More Legal Battles Ahead?
Key patents for gene-editing technology are at stake.
EMA Plans Pilot for Biosimilars Developers
Breadth and depth of established data will determine study approach.
What's Next for the Europe Biosimilars Market?
New report: biosimilars outlook for 2020.
